Company Information

SYNCOM FORMULATIONS (INDIA) LTD.

NSE : SYNCOMFBSE : 524470ISIN CODE : INE312C01025Industry : Pharmaceuticals & DrugsHouse : Private
BSE12.59-0.1 (-0.79 %)
PREV CLOSE ( ) 12.69
OPEN PRICE ( ) 12.60
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 337148
TODAY'S LOW / HIGH ( )12.26 12.70
52 WK LOW / HIGH ( )5.9 18.65
NSE12.55-0.1 (-0.79 %)
PREV CLOSE( ) 12.65
OPEN PRICE ( ) 12.65
BID PRICE (QTY) 12.55 (8675)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 813467
TODAY'S LOW / HIGH( ) 12.30 12.75
52 WK LOW / HIGH ( )5.9 18.65
ChairmanKedarmal Bankda
Managing DirectorVijay Shankarlal Bankda
Company SecretaryVaishali Agrawal
Non Executive Independent DirectorKrishna Das Neema
Vinod Kumar Kabra
Praveen Jindal
Ruchi Jindal
Ritesh Kumar Lunkad
Ankit Jain
Whole Time DirectorRinki Bankda
Incorporation Year : 21-06 1988

Registered Office :

Address : 7 Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai,
Maharashtra-400093 .

Phone : 022 26877711

Email :  finance@sfil.in 

URL : www.sfil.in

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.